David Steinberg

CBO Formation Bio. Serial biotech founder. Biotech, venture capital, pharma, science.

[Ben Liu @BenjamineYLiu]

AI is accelerating drug discovery — but none of that matters if we can't get medicines through development + clinical trials and into patients' hands. That's the bottleneck we're solving at @FormationBio.

Thanks @Forbes and @AmyFeldman for sharing our story. Grateful to our investors, partners, and most importantly the incredible Formation Bio team as we look to build this generation's enduring pharma company.

[David Steinberg @DavidASteinberg]

@Mykalt45 Love this! (Still took some wine to get through it…)

[Formation Bio @formationbio]

Indication landscaping is foundational to how we evaluate drug opportunities, but it’s complex, iterative, and data-heavy. In our latest post, we share how we built durable, AI-assisted workflows to support real-world indication research. https://t.co/brdoJnu5yv

[PhRMA @PhRMA]

There are only a few other areas where AI has the potential to change lives more than the discovery and development of new medicines to improve lives for patients.

We thank @jackdent and @BenjamineYLiu for this discussion about how America needs to continue to lead in biopharma R&D and harness AI to accelerate treatments and cures.

[David Steinberg @DavidASteinberg]

Read this post by @formationbio 's CTO @dan_neil if you want an absolute master class on what it means to build an AI-native organization, with concrete examples. This is not some futuristic fantasy, it's happening right now.

[Formation Bio @formationbio]

AI-native ≠ more AI tools. Our CTO explains what it means in practice: changing the shape of a pharma company from labor-proportional to system-proportional scale, and building an institutional memory that appreciates rather than decays. https://t.co/HJ1vqBsdto

[Formation Bio @formationbio]

Proud to announce that Formation Bio has acquired worldwide rights, excluding greater China, to FHND5032, a small-molecule miR-124 activator for autoimmune diseases. This marks our third acquisition in six months, and we plan to enter the clinic in 2026.

Go behind the scenes of the acquisition with our team in our latest video.

[Formation Bio @formationbio]

AI can’t change how work gets done if it can’t access your organization’s data or tools. Here’s how we built ARK, an MCP-powered platform connecting models, systems, and agents across Formation Bio. https://t.co/wM598qwrqM

[Ben Liu @BenjamineYLiu]

@jrkelly We are opening a Boston office because the biotech, data science, and tech talent in Boston uniquely great! Also, it's full of people who value intellectual rigor, the pursuit of knowledge, earnestness, and doing good for the world :).

[Ben Liu @BenjamineYLiu]

@formationbio is building the data foundation that will power the future of clinical development, turning a decade of unstructured trial data into insight and laying the groundwork for AI-powered study design. Read more about how we do it:

[Formation Bio @formationbio]

Today we're announcing a new addition to our pipeline: LNK01006, a next-generation CNS-penetrant TYK2 inhibitor licensed from @LynkPharma. Phase 1 is planned for the first half of 2026.

In our latest video, hear from our team who brought the LNK01006 deal to life, including more details on our "Known In New" strategy, and how our technology makes acquisitions like this possible.

[Formation Bio @formationbio]

Our CEO @BenjamineYLiu was recently on @a16z's Raising Health podcast. He shares how Formation Bio is building this generation’s AI-native pharma company, and reflects on what this could mean for the future of medicine.

Listen here: https://t.co/t8WObzVRCu

[David Steinberg @DavidASteinberg]

Excited to welcome our inaugural class of Entrepreneurs in Residence to @formationbio !

[Formation Bio @formationbio]

Formation Bio welcomes our first class of Entrepreneurs in Residence! These dealmaking veterans will help drive pipeline growth, partnerships & BD strategy.
Read more here: https://t.co/Bql1140Ajq

[David Steinberg @DavidASteinberg]

We at @formationbio are thrilled to be working with Mikael on his post-Pfizer journey

[Andrew Dunn @AndrewE_Dunn]

For his post-Pfizer era, Mikael Dolsten is already working with ~10 life science companies, ranging from large businesses to new startups

That includes Formation Bio, where he'll lead a drug-picking committee as an advisor.

My latest at @endpts: https://t.co/kvBT2f3Bp3

[Sam Altman @sama]

!!

[David Steinberg @DavidASteinberg]

2/basically as good as a human analyst for that problem, with output in minutes vs days

[David Steinberg @DavidASteinberg]

1/ Had an in depth brainstorm with GPT o1 that blew me away. Had to come up with metrics for team productivity - it took my parameters, came up with whole new ideas that balanced conflicting incentives, generated the formulae, then accurately modeled multiple nuanced scenarios.

[Andrew Dunn @AndrewE_Dunn]

“If we think about all the drug development activities, we think there’s a Muse for everything,” Formation Bio CEO Benjamine Liu said. “This all ladders up to a broader AI R&D scientist.”

A bold claim for a big vision from Liu — but a first step here: https://t.co/CRDt50qsgD

[Ben Liu @BenjamineYLiu]

Meet Muse, our latest AI innovation for drug development—a tool designed to optimize patient recruitment built together w. @sanofi and @OpenAI. Muse is an example of how AI systems are becoming capable of performing tasks that once required entire teams or organizations.
https://t.co/l6iNGDEqpp

[Rectify Pharma @RectifyPharma]

Welcome to our new Chief Business Officer, Bharat Reddy, Ph.D.! With deep business development expertise, Bharat’s leadership will be critical as we advance our first-in-class therapeutics to restore and enhance #ABCTransporter function. Read more: https://t.co/v8pyPFBR0z

[Be Biopharma @bebiopharma]

The U.S. FDA has granted Orphan Drug Designation to BE-101, a novel engineered B Cell medicine (BCM) being developed for the treatment of Hemophilia B. Full release here: https://t.co/woA8VzUqtK

#BCell #BeBold #BCellMedicines #BCMs